Effect of L-dopa on polycythemia.
A patient with Parkinson's disease, in whom polycythemia vera was known to be present for several years prior to the onset of parkinsonian symptoms, received treatment with a preparation consisting of L-dopa plus a decarboxylase inhibitor (Madopar). Improvement in the parkinsonian symptoms was associated with marked improvement in the polycythemia. A therapeutic trial of the same L-dopa preparation in 2 other patients with polycythemia had similar effects. The cases are presented and the possible central therapeutic effect of L-dopa is discussed.